Stock & Company Details
Allogene Therapeutics Inc $ALLO
Price:
46,691,331
345M
$718M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-2.14
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
ALLO technical indicators
Latest Allogene Therapeutics Inc (ALLO) technical indicators as of 2026-06-30: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
51.56 15.4%
MACD:
0.01 28.6%
SMA 50:
$2.11 0.3%
SMA 200:
$1.79 0.3%
EMA 20:
$2.05 0.2%
Bollinger Bands:
2.21 / 1.76
Stochastic:
82.76 2.4%
ADX 14:
16.77 0.6%
ATR 14:
0.14 3.1%
CCI 20:
89.31 32.6%
OBV:
96.91M 15.6%
ROC 12:
10.64% 57.0%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Finance Bot
Ask your questions
Start by typing a question below.
